Hims & Hers Health (HIMS) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HIMS shares.
View HIMS analyst ratings or view top-rated stocks.

9 brokerages have issued 1-year target prices for Hims & Hers Health's stock. Their HIMS share price forecasts range from $5.00 to $18.00. On average, they anticipate the company's stock price to reach $11.91 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts.

Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS shares have increased by 38.8% and is now trading at $8.8950.
View the best growth stocks for 2023 here.

Hims & Hers Health saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 20,940,000 shares, a decrease of 7.0% from the April 30th total of 22,510,000 shares. Based on an average daily volume of 3,860,000 shares, the short-interest ratio is currently 5.4 days. Approximately 17.0% of the shares of the company are sold short.
View Hims & Hers Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our HIMS earnings forecast.

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings results on Monday, May, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $190.80 million for the quarter, compared to analysts' expectations of $179.07 million. Hims & Hers Health had a negative net margin of 9.65% and a negative trailing twelve-month return on equity of 18.97%. The company's quarterly revenue was up 88.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) earnings per share.

ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), First Trust Small Cap Growth AlphaDEX Fund (FYC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Small Cap Core AlphaDEX Fund (FYX), iShares Micro-Cap ETF (IWC).iShares U.S. Healthcare Providers ETF (IHF).

Hims & Hers Health issued an update on its second quarter 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.00 million-$205.00 million, compared to the consensus revenue estimate of $183.30 million.

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Hims & Hers Health's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.29%), Institutional Venture Management XVI LLC (3.70%), Institutional Venture Management XV LLC (3.70%), Redpoint Management LLC (3.19%), Foresite Capital Management V LLC (1.79%) and State Street Corp (1.42%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HIMS stock can currently be purchased for approximately $8.90.

Hims & Hers Health (NYSE:HIMS) has a market capitalization of $1.86 billion and generates $526.92 million in revenue each year. The company earns $-65,680,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

The company employs 398 workers across the globe.

Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The official website for the company is www.forhims.com. The company can be reached via email at hims-ir@westwicke.com.